On November 21, 2017 Celgene Corporation (NASDAQ: CELG) reported that it plans to webcast an analyst and investor event being held at the American Society of Hematology (ASH) (Free ASH Whitepaper) meeting in Atlanta on December 10 (Press release, Celgene, NOV 21, 2017, View Source [SID1234522188]). The webcast will begin at 8pm ET and will be available in the Investor Relations section of the Company’s website at www.celgene.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 21, 2017 Exelixis, Inc. (NASDAQ: EXEL) reported that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the following two investor conferences in the coming weeks (Press release, Exelixis, NOV 21, 2017, View Source;p=RssLanding&cat=news&id=2318251 [SID1234522208]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Jaffray 29th Annual Healthcare Conference: Exelixis’ presentation is scheduled for 11:00 AM EST / 8:00 AM PST on Tuesday, November 28, 2017 in New York, NY.

Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference: Exelixis’ presentation is scheduled for 12:05 PM EST / 9:05 AM PST on Wednesday, November 29, 2017 in Boston, MA.

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.

GenSpera has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, GenSpera, 2017, NOV 20, 2017, View Source [SID1234522171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 20, 2017 Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported that it will be presenting at the 10th Annual LD Micro Main Event on Tuesday, December 5th at 8:30 AM PT/11:30 AM ET (Press release, Cellectar Biosciences, NOV 20, 2017, View Source [SID1234522173]). Jim Caruso, president and CEO of Cellectar, will present the company and meet with investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s presentation will also be webcast at View Source, and will be posted on the company’s website following the conference. The LD Micro Main Event will be held at the Luxe Sunset Bel Air Hotel in Los Angeles.

Oncbiomune has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, OncBioMune Pharmaceuticals, 2017, NOV 20, 2017, View Source [SID1234522178]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!